0001209191-22-040274.txt : 20220701
0001209191-22-040274.hdr.sgml : 20220701
20220701164355
ACCESSION NUMBER: 0001209191-22-040274
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220701
FILED AS OF DATE: 20220701
DATE AS OF CHANGE: 20220701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klencke Barbara
CENTRAL INDEX KEY: 0001647647
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 221062043
MAIL ADDRESS:
STREET 1: C/O SIERRA ONCOLOGY, INC.
STREET 2: 1820 GATEWAY DRIVE, SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
BUSINESS PHONE: (605) 376-8679
MAIL ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-01
1
0001290149
Sierra Oncology, Inc.
SRRA
0001647647
Klencke Barbara
C/O SIERRA ONCOLOGY, INC.
1820 GATEWAY DR., SUITE 110
SAN MATEO
CA
94404
0
1
0
0
Chief Medical Officer
Common Stock
2022-07-01
4
D
0
10000
55.00
D
0
D
Common Stock
2022-07-01
4
D
0
5000
55.00
D
0
I
By spouse
Stock Option (right to buy
268.20
2022-07-01
4
D
0
11744
0.00
D
2025-06-10
Common Stock
11744
0
D
Stock Option (right to buy)
263.20
2022-07-01
4
D
0
2061
0.00
D
2016-03-08
Common Stock
2061
0
D
Stock Option (right to buy)
72.80
2022-07-01
4
D
0
11399
0.00
D
2026-09-30
Common Stock
11399
0
D
Stock Option (right to buy)
58.00
2022-07-01
4
D
0
1749
0.00
D
2027-03-06
Common Stock
1749
0
D
Stock Option (right to buy)
94.40
2022-07-01
4
D
0
4508
0.00
D
2028-03-06
Common Stock
4508
0
D
Stock Option (right to buy)
78.40
2022-07-01
4
D
0
4999
0.00
D
2029-03-04
Common Stock
4999
0
D
Stock Option (right to buy)
13.31
2022-07-01
4
D
0
167091
0.00
D
2030-02-25
Common Stock
167091
0
D
Stock Option (right to buy)
12.15
2022-07-01
4
D
0
49000
0.00
D
2030-08-12
Common Stock
49000
0
D
Stock Option (right to buy)
16.73
2022-07-01
4
D
0
30000
0.00
D
2031-03-15
Common Stock
30000
0
D
Stock Option (right to buy)
31.54
2022-07-01
4
D
0
50000
0.00
D
2032-03-14
Common Stock
50000
0
D
The option fully vested on June 11, 2019.
Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
The option fully vested on January 1, 2020.
The option fully vested on September 30, 2019.
The option fully vested on January 1, 2021.
The option fully vested on January 1, 2022.
The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Mary Christina Thomson, Attorney-In-Fact for Barbara Klencke
2022-07-01